In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
News|Podcasts|August 14, 2026
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why data quality is the ceiling for all other trial modernization efforts, how CRAs are shifting from compliance monitors to data-enabled partners, and recognition of five rising industry leaders shaping pharma innovation.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new FAQ , we addressed data quality across the clinical trial lifecycle, framing it as a layered challenge manifesting differently at every stage from point-of-care sample collection to real-world data curation and wearable device integration. Data quality remains the ceiling on artificial intelligence, real-time oversight, and real-world evidence deployments, yet organizations still lack standardized solutions across trial phases. - In a
new contributed article , Chi-Hui Tang, senior strategic consultant at CluePoints, described how clinical research associates are evolving from compliance-focused manual monitors to data-enabled strategic site partners capable of using analytics to prioritize high-impact activities. Organizations need analytics training, clear operating models, and active change management to make the shift from activity-based monitoring to risk-proportionate oversight. Pharmaceutical Executive announced the 2026 Emerging Pharma Leader Awards , recognizing five rising leaders across R&D, operations, and innovation spanning Syndax Pharmaceuticals, Corsera Health, Regeneron, EVERSANA, and Inizio Engage. The honorees were selected for vision and drive in areas including artificial intelligence, scientific marketing, and company building.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
3
Comparing OpenAI and Mistral on Clinical Trial Matching
4
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
5